Treatment for ovarian hyperstimulation syndrome using an oral dopamine prodrug, docarpamine

Gynecological Endocrinology

Volumn 17, Issue 4, 2003, Pages 281-286

  Tsunoda, T ^a   Shibahara, H ^a   Hirano, Y ^a   Suzuki, T ^a   Fujiwara, H ^a   Takamizawa, S ^a   Ogawa, S ^b   Motoyama, M ^b   Suzuki, M ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b Utsunomiya Central Clinic   (Japan)

Author keywords

Docarpamine; Dopamine; OHSS; Ovarian Hyperstimulation Syndrome; Prodrug

Indexed keywords

ALBUMIN; DOCARPAMINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIURESIS; DRUG EFFECT; FEMALE; HOSPITALIZATION; HUMAN; OVARY DISEASE; PRIORITY JOURNAL; SIDE EFFECT; TABLET; URINE VOLUME;

EID: 0042834004     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/gye.17.4.281.286     Document Type: Article

References (26)

1. Schenker JG, Weinstein D. Ovarian hyperstimulation syndrome. Fertil Steril 1978;30:255-68
2. Haning RU, Strawn EV, Nolten WE. Pathophysiology of the ovarian hyperstimulation syndrome. Obstet Gynecol 1989;66:220-4
3. Navot D, Margalioth EJ, Laufer N, et al. Direct correlation between plasma rennin activity and severity of the ovarian hyperstimulation syndrome. Fertil Steril 1987;40:57-61
4. Meldrum DR, Wisot A, Hamilton F, et al. Routine pituitary suppression with leuprolide before ovarian stimulation for oocyte retrieval. Fertil Steril 1989;51:455-9
5. Brinsden PR, Wada I, Tan SL, et al. Diagnosis, prevention and management of ovarian hyperstimulation syndrome. Br J Obstet Gynaecol 1995;102:767-72
6. Ferraretti AP, Gianaroli L, Diotallevi L, et al. Dopamine treatment for severe ovarian hyperstimulation syndrome. Hum Reprod 1992;7:180-3
7. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992;58:249-61
8. Morris RS, Miller C, Jacobs L, et al. Conservative management of ovarian hyperstimulation syndrome. J Reprod Med 1995;40:711-14
9. Thaler I, Yoffe N, Kaftory JK, et al. Treatment of ovarian hyperstimulation syndrome: the physiologic basis for a modified approach. Fertil Steril 1981;36:110-13
10. Borenstein R, Elhalah U, Lunenfeld B, et al. Severe ovarian hyperstimulation syndrome: a reevaluated therapeutic approach. Fertil Steril 1989;51:791-5
11. Aboulghar MA, Mansour RT, Serour GI, et al. Ultrasonically guided vaginal aspiration of ascites in the treatment of severe ovarian hyperstimulation syndrome. Fertil Steril 1990;53:933-5
12. McDonald RH, Goldberg LI, McNay JL, et al. Effect of dopamine in man: augmentation of sodium excretion, glomerular filtration rate, and renal plasma flow. J Clin Invest 1964;43:1116-24
13. Goldberg LI. Cardiovascular and renal actions of dopamine: potential clinical applications. Pharmacol Rev 1972;24:1-29
14. Yoshikawa M, Endo H, Otsuka M. Comparative study of the disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O, O-bis (ethoxycarbonyl) dopamine (TA-870) and dopamine hydrochloride in rats and dogs. Drug Metab Dispos 1988;16:754-8
15. Yoshikawa M, Endo H, Komatsu K. Disposition of a new orally active dopamme prodrug, N-(N-acetyl-L-methionyl)-O, O-bis (ethoxycarbonyl) dopamine (TA-870) in humans. Drug Metab Dispos 1990;18:212-17
16. Yamaguchi I, Nishiyama S, Akimoto Y, et al. A novel orally active dopamine prodrug TA-870. I. Renal and cardiovascular effects and plasma levels of free dopamine in dogs and rats. J Cardiovasc Pharmacol 1989;13:879-86
17. Orvieto R, Ben-Rafael Z. Role of intravenous albumin in the prevention of severe ovarian hyperstimulation syndrome. Hum Reprod 1998;13:3306-9
18. Medical Research International, Society for Assisted Reproductive Technology (SART), The American Fertility Society. In vitro fertilization-embryo transfer (IVF-ET) in the United States: 1990 results from the IVF-ET registry. Fertil Steril 1992;57:15-24
19. Aboulghar MA, Mansour RT, Serour GI, et al. Auto-transfusion of the ascitic fluid in the treatment of severe ovarian hyperstimulation syndrome. Fertil Steril 1992;58:1056-9
20. Fukaya T, Chida S, Terada Y, et al. Treatment of severe ovarian hyperstimulation syndrome by ultrafiltration and reinfusion of ascitic fluid. Fertil Steril 1994;61:561-4
21. Koike T, Araki S, Minakami H, et al. Clinical efficacy of peritoneovenous shunting for the treatment of severe ovarian hyperstimulation syndrome. Hum Reprod 2000;15:113-17
22. Takamizawa S, Shibahara H, Taneichi A, et al. Dynamic changes of the immunoglobulins in patients with severe ovarian hyperstimulation syndrome: efficacy of a novel treatment using peritoneovenous shunt. Am J Reprod Immunol 2002;47:25-30
23. Matsubayashi K, Ueda Y, Ogino H, et al. Oral administration of the dopamine prodrug docarpamine shortens need for drip infusion of dopamine in patients with low cardiac output syndrome after cardiac surgery. Thorac Cardiovasc Surg 1999;47:352-6
24. Watarida S, Shiraishi S, Sugita T, et al. Effects of docarpamine on hemodynamics after open heart surgery in children. Ann Thorac Cardiovasc Surg 2000;6:106-9
25. Funasaki T, Tsutumi M, Takase S, et al. Effects of a new orally active dopamine prodrug, docarpamine, on refractory ascites: a pilot study. Am J Gastroenterol 1999;94:2475-81
26. Ogawa H, Kusukawa M, Matsui S. Clinical efficacy of TA-870, a new oral dopamine in patients with tapering of dopamine: multiclinical cooperative study [in Japanese]. Yakuritochiryo 1991;19:1907-31